BridgeMD
New treatment option for Invasive Breast Carcinoma
Official title Application of Single-Port Robot-Assisted Breast-Conserving Surgery Via Axillary Approach for Breast Cancer.
ClinicalTrials.gov ID: NCT06738654
What this study is testing
- What it's testing
- Evaluate the safety,feasibility and quality of life(QoL)of single-port robotic surgery in breast-conserving surgery, compare and analyze the advantages and disadvantages of single-port robotic surgery and open surgery in terms of complications, postoperative complications, perioperative recovery effects, and safety in breast cancer breast-conserving surgery, in order to select a more effective and safe surgical method. Subjects who meet the inclusion criteria will enter the research process, with surgery including SPr-breast-conserving surgery or open-breast-conserving surgery, and the choice of the two surgical methods is based on the patient's financial situation and the availability of equipment;
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65, women only
You may be able to join if
- The patient himself has very high requirements for beauty, and requires no scar on the chest;
- No chest surgery and radiotherapy.
- No contraindications to surgery and anesthesia.
- Clinical I, stage of early breast cancer and the breast has an appropriate volume, can maintain a good breast shape after surgery.
- Patients in the clinical period who meet the standard of breast conservation surgery after preoperative treatment.
You likely can't join if
- Inflammatory breast cancer.
- The tumor is extensive and it's difficult to achieve negative margins or an ideal breast - conserving appearance.
- Diffusely distributed malignant - characteristic calcifications.
- The margin is positive after local extensive tumor resection, and a negative margin in pathological examination still can't be ensured after re -...
- The patient refuses.
See the full eligibility criteria
- The patient himself has very high requirements for beauty, and requires no scar on the chest;
- No chest surgery and radiotherapy.
- No contraindications to surgery and anesthesia.
- Clinical I, stage of early breast cancer and the breast has an appropriate volume, can maintain a good breast shape after surgery.
- Patients in the clinical period who meet the standard of breast conservation surgery after preoperative treatment.
- Age: 18 and 65 years old.
- Inflammatory breast cancer.
- The tumor is extensive and it's difficult to achieve negative margins or an ideal breast - conserving appearance.
- Diffusely distributed malignant - characteristic calcifications.
- The margin is positive after local extensive tumor resection, and a negative margin in pathological examination still can't be ensured after re - resection.
- The patient refuses.
The study team makes the final eligibility decision.
Where it's taking place
- Chongqing, Chongqing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chongqing, Chongqing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.